Tirzepatide · 39 amino acids

EloraTZP: Results for Lilly's Amylin Plus Tirzepatide Combo


EloraTZP is an investigational once-weekly combination from Eli Lilly that pairs tirzepatide (the medicine in Zepbound and Mounjaro) with eloralintide, an experimental amylin peptide. In a 48-week phase 2 trial presented at the EASD meeting on September 30, 2026, the highest dose led to 23.3% average weight loss in adults with obesity and type 2 diabetes, versus 14.8% with tirzepatide alone. It is not approved, side effects were more common with the combination, and Lilly plans to start phase 3 trials by the end of 2026.

Key facts

What is EloraTZP?

EloraTZP combines two peptide medicines that act on different appetite hormones. Tirzepatide activates both the GLP-1 and GIP receptors and is already FDA-approved for weight management and type 2 diabetes. Eloralintide mimics amylin, a hormone released alongside insulin after meals that is involved in feeling full. Lilly describes eloralintide as a once-weekly, selective amylin receptor agonist.

The idea is the same one behind Novo Nordisk’s CagriSema: pair a GLP-1 medicine with an amylin peptide and see whether the two add up. Our post on CagriSema’s EASD data and FDA timeline covers Novo’s version. If you are new to the idea that these medicines are peptides at all, start with why GLP-1s are peptides.

What did the phase 2 trial find?

The study enrolled 367 adults in the US and Argentina who had obesity or overweight plus type 2 diabetes. Their average starting weight was 105.4 kg and their average HbA1c was 8.1%. People were randomized to placebo, eloralintide alone, tirzepatide 15 mg alone, or one of four combinations (eloralintide 3, 6 or 9 mg with tirzepatide 5, 10 or 15 mg). Doses were raised step by step every 4 weeks.

After 48 weeks:

Why this matters: people with type 2 diabetes usually lose less weight on GLP-1 medicines than people without it. A result above 20% in this group is notable, and the trial was designed to show what the combination adds over tirzepatide on its own.

Side effects, told plainly

The most common side effects were gastrointestinal, generally mild or moderate, and clustered during the dose escalation period. They were more frequent with the combination than with either medicine alone. The share of people who stopped treatment because of side effects ranged from 10.8% to 27.0% in the combination groups, compared with 0% to 10.8% on eloralintide alone, 2.9% on tirzepatide alone and 16.7% on placebo, as reported by HCPLive.

That gap is the main caveat. Lilly says phase 3 will use an optimized escalation schedule, which is meant to make the start of treatment easier to tolerate. Whether it does is something the next trials will need to show.

Other honest limits

When could EloraTZP be available?

Not soon. Lilly plans to begin phase 3 trials of a single co-formulated EloraTZP product by the end of 2026, and phase 3 trials of eloralintide on its own are already under way. Phase 3 programs usually take years before a filing. Until then, eloralintide and EloraTZP can only be received inside a clinical trial. Anything sold online under those names is not an approved product, and there is no legal compounded version. For how unapproved peptides are treated today, see our legal status tracker.

What it means for you

EloraTZP is good news for people living with obesity and type 2 diabetes: an amylin peptide added to an approved medicine produced more weight loss and similar or better blood sugar control than tirzepatide alone. It is early, investigational and harder to tolerate in this trial. Tirzepatide itself is approved today, and a licensed provider can talk through whether it or another approved option fits. Our GLP-1 price tracker and semaglutide vs tirzepatide guide can help you prepare for that conversation.

Sources

Educational content only, not medical advice. Talk to a licensed provider about whether any medicine is right for you.

← All articles